Effect of Coenzyme Qon Insulin Resistance in Korean Patients with Prediabetes: A Pilot Single-Center, Randomized, Double-Blind, Placebo-Controlled Study.
Biomed Res Int. 2018 ;2018:1613247. Epub 2018 Jul 29. PMID: 30151373
Introduction: This study aimed to examine whether administration of coenzyme Q10, an antioxidant, improves insulin resistance in patients with prediabetes. The study design was a pilot single-center, randomized, double-blind, placebo-controlled trial.
Methods: This pilot single-center, randomized, double-blind, placebo-controlled trial included a total of 80 adults (aged≥20 years) with impaired glucose tolerance. After the initial screening visit, subjects were assigned to either the experimental (n = 40) or placebo (n = 40) group via simple randomization. Insulin resistance was represented as the insulin resistance index estimated by homeostasis model assessment(HOMA-IR).
Results: After the 8-week treatment period, the coenzyme group exhibited a significant decrease in the HOMA-IR (P<.001). The free oxygen radical and coenzyme Q10 concentrations were found to correlate significantly (P<.001). However, no significant changes in fasting blood glucose, insulin, and glycated hemoglobin levels were observed in either group. Additionally, no adverse events occurred in either group.
Conclusion: Patients with prediabetes who were administered coenzyme Q10 showed a significant reduction in HOMA-IR values. Therefore, administration of coenzyme Q10 in patients with impaired glucose tolerance may slow the progression from prediabetes to overt diabetes.